Studies on antitumor and myelotoxic effect of Ledakrin and its selected analogues.
Ledakrin (Nitracrine) and its three analogues (C-846, C-857, C-1006) selected in primary in vitro and in vivo screening systems have been tested for antitumor activity in Lewis lung carcinoma, B16 melanoma of 16/C mammary adenocarcinoma bearing mice. Their effect on mouse bone marrow stem cells has also been evaluated by means of CFU-S technique. None of the tested compounds, including Ledakrin, revealed anti-tumor activity. Their bone marrow toxicity was minimal and comparable with that of Bleomycin.